No Picture
News

NeuroSense Therapeutics announces the appointment of Mark Leuchtenberger as Chairman of the Board

CAMBRIDGE, Mass.: CAMBRIDGE, Mass., Sept. 29, 2021 /PRNewswire/ — NeuroSense Therapeutics, a clinical stage biotechnology company in the field of CNS, is pleased to announce the appointment of Mark Leuchtenberger as its new Chairman of the Board of Directors. Mr. Leuchtenberger has over 25 years of experience as a senior… Click here to view original post… […]

No Picture
News

MetaCell launches innovative Cloud Hosting for life science and healthcare

CAMBRIDGE, Mass.: CAMBRIDGE, Mass., Sept. 29, 2021 /PRNewswire/ — MetaCell, an innovative life science software company specialized in creating cutting-edge research software for major pharma, biotech, and academic institutions, has launched MetaCell Cloud Hosting – a brand new online product providing advanced cloud computing solutions to facilitate research and innovation… Click here to view original post… […]

No Picture
News

Wiley Accelerates Digital Transformation to Enable Seamless Access to Research and Educational Resources Globally With Dynatrace

WALTHAM, Mass.–(BUSINESS WIRE)–Software intelligence company Dynatrace (NYSE: DT) today announced Wiley is using the Dynatrace® platform to accelerate digital innovation. Wiley has been a leader in research and education for more than 200 years, helping learners, institutions, and corporations achieve their goals. As the industry and job market rapidly evolve,… Click here to view original post… […]

No Picture
News

Immunologist Expert Dr. Paul Peter Tak Joins GoodCell as Strategic Advisor

WALTHAM, Mass.: WALTHAM, Mass., Sept. 29, 2021 /PRNewswire/ — GoodCell, a medically-actionable service to identify, track and respond to health risks, is expanding its strategic advisors with the appointment of Paul Peter Tak, M.D., Ph.D. Dr. Tak is a world-renowned immunologist, drug developer, pharmaceutical CEO and entrepreneur with over 25… Click here to view original post… […]

No Picture
News

Alnylam Continues Scientific Leadership in Advancement of RNAi Therapeutics at the 17th Annual Meeting of the Oligonucleotides Therapeutics Society

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today new pre-clinical research results demonstrating continued RNAi therapeutics platform innovation and scientific leadership. The research was presented at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), held virtually from September 26 – 29, 2021…. Click here to view original post… […]

No Picture
News

VBI Vaccines Announces New Preclinical Data and Initiation of VBI-2905 Clinical Study Targeting Broadened Immunity Against COVID-19 and Variants of Concern

CAMBRIDGE, Mass.–(BUSINESS WIRE)–VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced positive results from multiple preclinical studies against several COVID-19 variants of concern as well as the initiation of dosing in the Phase 1b portion… Click here to view original post… […]

No Picture
News

Syros Announces First Patient in Dose Confirmation Study of SY-2101, a Novel Oral Form of Arsenic Trioxide, in Acute Promyelocytic Leukemia

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the first patient has been dosed in the dose confirmation study of SY-2101, a novel oral form of arsenic trioxide (ATO). The trial will evaluate the pharmacokinetics (PK), safety,… Click here to view original post… […]